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Abstract Dose is an important parameter in terms of both
efficacy and adverse effects in pharmacological treatment of
atrial fibrillation (AF). Both of the class III antiarrhythmics
dofetilide and amiodarone have documented anti-AF effects.
While dofetilide has dose-related ventricular side effects, ami-
odarone primarily has adverse non-cardiac effects.
Pharmacological inhibition of small conductance Ca2+-acti-
vated K+ (SK) channels has recently been reported to be anti-
arrhythmic in a number of animal AF models. In a
Langendorff model of acutely induced AF on guinea pig
hearts, it was investigated whether a combination of the SK
channel blocker N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-
amine (ICA) together with either dofetilide or amiodarone
provided a synergistic effect. The duration of AF was reduced
with otherwise subefficacious concentrations of either
dofetilide or amiodarone when combined with ICA, also at a
subefficacious concentration. At a concentration level effec-
tive as monotherapy, dofetilide produced a marked increase in
the QT interval. This QT prolonging effect was absent when
combined with ICA at non-efficacious monotherapy concen-
trations. The results thereby reveal that combination of
subefficacious concentrations of an SK channel blocker and
either dofetilide or amiodarone can maintain anti-AF proper-
ties, while the risk of ventricular arrhythmias is reduced.
Keywords Combination therapy . Antiarrhythmic drugs .
QT prolongation . Amiodarone . Dofetilide . hERG1 and
calcium-activated potassium channels
Abbreviations
AF Atrial fibrillation
ICA N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine
SK Small conductance Ca2+-activated K+
ACh Acetylcholine
TdP Torsade de Pointes
BID Bis in die (twice a day)
Introduction
The Vaughan Williams class III antiarrhythmics represent
potassium-channel blockers that are often used to convert
and prevent the recurrence of atrial fibrillation (AF).
Amiodarone is one of the most commonly prescribed antiar-
rhythmic agents and is currently the most effective drug on the
market for prevention of AF [26]. However, the use of amio-
darone is restricted by severe non-cardiac side effects includ-
ing, but not limited to, pulmonary fibrosis, photosensitivity,
thyroid dysfunctions, and neurological disorders [1]. It has
been reported that 18 % of patients had to discontinue the
use of amiodarone because of adverse events [26].
Amiodarone is classified as a class III antiarrhythmic agent
because of its inhibition of the rapid and slow delayed rectifier
potassium currents IKr and IKs, respectively, but it also inhibits
other cardiac ion channels conducting sodium (INa), calcium
(ICa,L), and potassium (transient outward— Ito) [18]. Despite
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the reported prolongation of the QT interval in patients, ami-
odarone shows little propensity for induction of Torsades de
Pointes (TdP) [19].
Dofetilide was, until recently, believed to be a specific IKr
blocker; however, new data indicate that it also increases the
late sodium current [39]. IKr is conducted through hERG1
channels, which are expressed in both atria and ventricle
[15, 27]. Unlike other antiarrhythmic agents, dofetilide does
not increase mortality in patients with recent myocardial in-
farction or congestive heart failure and is therefore important
as an alternative to amiodarone for the pharmacological con-
version of AF in patients at high risk of sudden cardiac death
[24]. However, dofetilide prolongs the QT interval, believed
to increase the risk of potentially lethal TdP arrhythmias, and
has been withdrawn from the European market. The SAFIRE-
D study showed an increase in AF and atrial flutter conversion
rates from 9.8 to 29.9 % when increasing the dofetilide dose
from 250 to 500 μg bis in die (BID) [29]. The incidences of
TdP caused by dofetilide also increased in a dose-dependent
manner, from 0.3 % with a dose of 250 μg BID to 10.5 %
when the dose was above 500 μg BID [25].
The small conductance calcium-activated potassium (SK)
channels, mediating ISK, are a family of potassium channel
proteins with three highly homologous members (SK1, SK2,
and SK3), all reportedly expressed in the heart [36], but are
also known to play important functions in the CNS and vas-
culature [33]. SK channels, which have been reported to be
localized in close proximity to L-type calcium channels, are
gated following submicromolar increases in cytoplasmic cal-
cium [38]. This suggests a unique role for these channels to
translate increase in intracellular Ca2+ to repolarization [20].
Functionally, SK channels have been reported to play a more
prominent role in the atria compared to non-diseased ventri-
cles [36]. However, in failing human and rabbit ventricle, ISK
has been suggested to participate in repolarization [4, 40]. In
the atria, pharmacological inhibition of these channels has
been found to increase the effective refractory period (ERP)
and to revert and protect against AF in a number of animal
models of induced AF [7, 8, 12, 30]. Single-nucleotide poly-
morphisms in the KCNN3 gene encoding SK3 channels have
been associated with AF risk, directly linking SK channels to
clinical AF [3, 9, 10]. In isolated atrial myocytes and in tra-
beculae muscle, strips from patients in sinus rhythm SK chan-
nel inhibition prolonged action potential duration (APD) and
ERP, suggesting the involvement of SK channel in human
repolarization and the antiarrhythmic potential of SK channel
inhibition [31]. In addition, we have previously reported SK
inhibition to depolarize the resting membrane potential in both
human and rat atria [31, 32]. Depolarization of the diastolic
potential may cause voltage-dependent inactivation reducing
sodium-channel availability, which will result in both slowing
of the conduction and further prolongation of ERP. Several
small molecule inhibitors of SK channels are known [11].
Presently, ICA seems to be the most specific, having at least
40-fold specificity over other relevant cardiac ion channels
[31, 32].
We have previously reported SK channel inhibition to act
synergistically with sodium channel blockers [16]; however,
whether the SK channel inhibition in combination with class
III antiarrhythmics has an anti-AF effect has not been ad-
dressed. Therefore, in a Langendorff AF model on guinea
pig hearts, the relatively selective SK channel pore blocker,
ICA, was combined with either dofetilide or amiodarone in
doses that were subefficacious as a monotherapy to investigate
whether it was possible to maintain efficacy and thereby re-
duce adverse effects.
Methods
The studies were performed under a license from the Danish
Ministry of Justice (license no. 2012/15-2934-00345) and in
accordance with the Danish guidelines for animal experiments
according to the European Commission Directive 86/609/
EEC.
Langendorff preparation
A total of 53 isolated guinea pig hearts were prepared as pre-
viously described [17]. Dunkin Hartley guinea pigs weighing
between 350 and 500 g were anesthetized, the heart removed
and mounted in a Langendorff setup (Hugo Sachs-Harvard
Apparatus GmbH) and perfused through the aorta with
Krebs–Henseleit solution [16] at constant oxygenation with
a O2/CO2 mixture of 95/5 % at 37 °C. Monophasic action
potential (MAP) electrodes were placed on the left atrium,
the right atrium, the left ventricle, and the right ventricle. A
pacing electrode was placed on the right atrium and the heart
was allowed to stabilize for 30 min before recordings of elec-
trophysiological parameters were initiated. The electrocardio-
gram (ECG) was obtained with three ECG electrodes placed
in close proximity to the heart. All data were acquired using
the 16-channel PowerLab system (ADInstruments). The pac-
ing stimuli were twice the diastolic threshold with duration of
2 ms. The coronary flow was unaltered following application
of compounds as compared to time-matched controls.
Compounds
The SK blocker N-(pyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-
amine (ICA) was supplied by Acesion Pharma. All other
chemicals were obtained from Sigma-Aldrich. All compounds
were dissolved as stock solutions of 10 mM in DMSO. The
final DMSO concentrations never exceeded 0.1 %.
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Electrophysiology
Dofetilide or amiodarone was tested alone or in combination
with ICA, all in subefficacious concentrations. The atrial
effective refractory period (aERP) was measured (10 basic
stimuli S1 followed by a premature S2 stimulus in increasing
steps of 2 ms) at baseline and every 5 min until the end of the
30-min period, with 1.0 μM dofetilide or 1.0 μM amiodarone
a
b
30 min. 
stabilization
30 min. aERP 
measurements
ACh
Burst pacing and 
AF duration measurements.
Compound(s)
S1S2S1
LA:
S2 induced extra AP 
LV:
ECG:
Stimulation:
ECG:
LA:
LV:
AF
Stimulation:
Burst pace
400 ms 
400 ms 
S2
Fig. 1 Induction and treatment
protocol together with
representative control recordings.
a Experimental protocol for aERP
and AF duration measurements.
After 30 min of stabilization
following mounting in the
Langendorff configuration,
compound or combination of
compounds was added and aERP
was measured every 5 min for
30 min. The hearts were paced at
5 Hz, except while performing the
10-Hz aERP measurements.
Induction of AF was the
attempted by shortening of ERP
by ACh and burst pacing. b
Representative traces from a
control experiment displaying the
procedure for measuring aERP
(top) and induction of persistent
AF (bottom). LA left atrium,
LV left ventricle
Table 1 Data from the
experiments: Displaying atrial
effective refractory periods
(aERP), AF durations, the
difference in QT interval at 5 Hz
before and after addition of
compounds listed as ΔQT
Number aERP 5 Hz
(ms)
aERP 10 Hz
(ms)
AF duration
(s)
ΔQT (ms)
Control 6 56 ± 2 48 ± 2 35.8 ± 7.4 −2.6 ± 1.2
ICA (0.1 μM) 7 68 ± 3 58 ± 3 34.7 ± 8.0 1.4 ± 2.7
Dofetilide (1.0 μM) 7 89 ± 2a,b 84 ± 3a,b 36.2 ± 4.5 11.7 ± 4.6
ICA (0.1 μM) and dofetilide
(1.0 μM)
6 94 ± 4a,b 91 ± 4a,b 1.1 ± 0.9a,b,c 7.4 ± 3.4
Amiodarone (1.0 μM) 6 66 ± 4 67 ± 5a 25.9 ± 6.7 5.8 ± 4.6
ICA (0.1 μM) and
amiodarone (1.0 μM)
8 86 ± 4a,b,c 90 ± 3a,b,c 8.0 ± 4.4a,b,c 4.6 ± 2.2
Dofetilide (3.0 μM) 7 ND ND 0.4 ± 0.1 31.1 ± 5.9 a,b,e,d
Amiodarone (3.0 μM) 6 ND ND 1.2 ± 0.8a 5.3 ± 4.9
The aERP values noted is after 30 min of compound perfusion
ND not done
a Significant difference from control
b Significant difference from ICA (0.1 μM )
c Significant difference from amiodarone (1.0 μM)
d Significant difference from dofetilide (1.0 μM)
e Significant difference from ICA (0.1 μM) and dofetilide (1.0 μM)
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added to the buffer either as monotherapy or in combination
with 0.1 μM ICA. The aERP was measured at pacing rates of
5 and 10 Hz. Subsequently, 1 μM ACh was added to the
perfusate and AF induction was attempted 40 times with burst
pacing (50 Hz, 10 V) or until sustained AF (>3 min) was
obtained.
In the second part of the experiments, dofetilide (3.0 μM)
and amiodarone (3.0 μM) in concentrations that were effec-
tive as monotherapy were compared to the respective combi-
nation therapy on the proarrhythmic parameters: QT, triangu-
lation, and instability of APD90.
Data analysis
Poincaré plot was drawn by plotting a given APD90 as a func-
tion of the previous APD90, and short-term variability (STV)
was calculated from 49 subsequent APD90s using (STV ¼
Σ│Dnþ1–Dn│/[49*√2]) [35].
Data analyses were performed using GraphPad Prism 5 and
LabChart 7 (ADInstruments). Data are summarized using the
mean ± SEM. Repeated measures two-way ANOVA with
Bonferroni post hoc tests was used to compare mean values
of aERP, QT, and triangulation. For the statistics, the AF du-
rations were log-transformed and repeated measures one-way
ANOVAwith Bonferroni post hoc tests was used to compare
the mean values of the AF duration,ΔQT, and STV. Values of
P < 0.05 were considered statistically significant (denoted by
asterisks in figures). Values of P < 0.01 and P < 0.001 are
denoted by ** and ***, respectively.
Results
Guinea pig hearts express a number of the same ionic currents as
humans, including IKr and IKs [2], and both atrial and ventricular
arrhythmias can be triggered in these hearts [6, 16]. Therefore, to
investigate whether a given pharmacological treatment could re-
vert and prevent acutely induced AF, we isolated guinea pig
hearts and mounted them in a Langendorff configuration where
they were perfused with oxygenated 37 °C saline buffer. In this
model, test compounds can be supplied to the buffer, electrical
stimulation can be applied (used both for pacing and refractory
measurements), and electrical activity recorded by monophasic
action potential (MAP) and ECG electrodes. Further, application
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Fig. 2 Atrial refractoriness following perfusion with dofetilide and ICA.
Atrial effective refractory period (aERP) of ICA and dofetilide (Dof) in
concentrations subefficacious as independent monotherapies, either alone
or in combination, at pacing rates of 5 and 10 Hz. *ICA and dofetilide
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Fig. 3 Atrial refractoriness
following perfusion with
amiodarone and ICA. Atrial
effective refractory period (aERP)
of ICA and amiodarone (Amio) at
concentrations subefficacious as
independent monotherapies,
either alone or in combination, at
pacing rates of 5 and 10 Hz.
*Significant difference from the
control. †Significant difference
from ICA. ‡Significant difference
from amiodarone
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of acetylcholine (ACh) drastically increases AF vulnerability by
reducing the refractoriness of the atrial tissue and if burst pacing
is applied, AF can be induced (Fig. 1) [17].
Before performing the combination studies with ICA together
with either dofetilide or amiodarone, the effective dose for
reverting AF, when supplied as monotherapy, was tested. These
investigations showed that 0.3 μM ICA, 3.0 μM dofetilide, and
3.0 μM amiodarone effectively reverted AF (Table 1). As a con-
sequence, 0.1 μM ICA, 1 μM dofetilide, and 1 μM amiodarone
were applied in the combination study.
Atrial refractoriness with combination therapy
To investigate whether the combinations of ICA and ei-
ther dofetilide or amiodarone have additive effects on
atrial electrophysiology and AF prevention, a series of
Langendorff experiments was performed (Table 1).
aERPs were measured every 5 min prior to and after com-
pound perfusion (Fig. 1). The SK blocker ICA, at a con-
centration of 0.1 μM, only revealed a non-significant ten-
dency toward increase in aERP at both 5 and 10 Hz com-
pared to control (Fig. 2 and Table 1). Both 1.0 μM
dofetilide alone and the combination of dofetilide and
ICA increased aERP significantly at both 5 and 10 Hz
compared to control and ICA alone, but no differences
in aERP were observed between these two treatment
groups (Fig. 2 and Table 1).
Perfusion with 1.0 μM amiodarone increased aERP,
although only significantly at 10 Hz, compared to control.
This effect of borderline aERP prolongation observed for
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Fig. 4 Combination treatment with either dofetilide or amiodarone and
ICA reduces AF burden. a Representative recordings from the induction
of AF after 30 min of application of dofetilide (1.0 μM) (start and
reversion of AF shown, while the middle 154 s is not shown). AF was
induced by addition of acetylcholine and burst pacing. LA Left atrium, LV
left ventricle. b Combination of ICA (0.1 μM) and dofetilide (1.0 μM).
Note, the addition of ACh induces third degree AV block in guinea pig
Langendorff hearts and ventricles therefore following their own intrinsic
beating. c AF duration for control, ICA, dofetilide, and ICA + dofetilide
groups. The combination with ICA and dofetilide reduced AF duration
compared to the control and the monotherapies. The monotherapies did
not reduce AF durations compared to the control deeming them
subefficacious. d The combination of ICA and amiodarone reduced the
AF durations compared to control and the subefficacious monotherapies.
*Significant difference from the control. †Significant difference from
ICA. ‡Significant difference from dofetilide. §Significant difference
from amiodarone
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both ICA and amiodarone is drastically amplified when
combining the two compounds (Fig. 3 and Table 1). The
onset of effect on aERP was slower for the ICA + amio-
darone group than for the dofetilide and ICA + dofetilide
group, indicating that amiodarone needs longer time to
reach the ion channel targets (IKr and IKs) than does
dofetilide.
AF prevention with combination therapy
With the test compound still in the perfusion buffer,
1.0 μM ACh was added and burst pacing induction of
AF was attempted 40 times. In non-protected hearts, this
resulted in short runs of AF with an average of 35 s
(representative recording in Fig. 4a). In protected hearts,
this AF duration was significantly reduced or even absent
(representative recording in Fig. 4b). The AF duration
time was measured in the time-matched control hearts,
in hearts receiving monotherapy, and in hearts with either
combination of drugs. The monotherapies of ICA
(0.1 μM) and dofetilide (1.0 μM) did not reduce the AF
durations compared to the control (Table 1). In contrast,
with 3.0 μM dofetilide AF durations were reduced com-
pared to the control (Table 1). The combination therapy of
0.1 μM ICA and 1.0 μM dofetilide significantly reduced
the average AF duration compared to the control, ICA,
and 1.0 μM dofetilide alone (Fig. 4c). 1.0 μM amiodarone
as a monotherapy did not reduce the AF duration signif-
icantly compared to the control (Table 1). However, in-
creasing the concentration to 3.0 μM amiodarone resulted
in reduced AF duration (Table 1). When 0.1 μM ICA and
1.0 μM amiodarone were combined, the AF duration was
significantly reduced compared to the control, ICA, and
1.0 μM amiodarone alone (Fig. 4d).
Proarrhythmic effects on ventricular electrophysiology
For some pharmacological compounds, a correlation be-
tween QT prolongation and increased propensity for TdP
has been demonstrated. We therefore investigated the QT
prolonging effect of the dose of dofetilide and amiodarone
that was effective in preventing AF as a monotherapy and
compared this to the respective combinations in concen-
tra t ions that were effect ive in combinat ion but
subefficacious as monotherapies. Dofetilide (3.0 μM) in-
creased the QT interval by 26 % compared to baseline
(Fig. 5), which was significantly higher compared to the
6 % prolongation caused by the combination of ICA
(0.1 μM) and dofetilide (1.0 μM). The 3.0 μM amioda-
rone did not increase the QT interval compared to the
baseline or the combination of ICA (0.1 μM) and amio-
darone (1.0 μM).
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Fig. 5 Compound-induced effect on QT interval. Potential QT interval
prolongation caused by the compounds were investigated by comparing
relative QT durations before and after 30-min perfusion with compounds.
a Investigations of the dofetilide groups revealed that only dofetilide
(3.0 μM) increased the QT interval significant compared to the
combination of ICA (0.1 μM) and dofetilide (1.0 μM), which were the
only groups that proved antiarrhythmic. b In the amiodarone groups, no
QT interval prolongation was found. **dofetilide (3.0 μM) significant
difference from the combination of ICA (0.1 μM) and dofetilide
(1.0 μM). c Spatial dispersion in repolarization between right and left
ventricle recorded before and after perfusion with dofetilide (3.0 μM)
and dofetilide (1.0 μM) and ICA (0.1 μM). The repolarization time was
recorded at 90 % repolarization (APD90) with MAP electrodes placed on
the epicardial surface of the right and left ventricles
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To investigate the spatial dispersion in repolarization, APD90
recorded from the left and right ventricle was analyzed (Fig. 5).
Following perfusion with 3.0 μM dofetilide, both right and left
ventricles have prolonged repolarization time. However, the right
ventricular APD90 was increased more profoundly than the left
ventricular APD90, indicating an increased spatial dispersion in
repolarization. Perfusion with lower concentration of dofetilide
(1.0 μM) together with 0.1 μM ICA did not increase the spatial
dispersion.
Another important parameter for estimating potential ventric-
ular proarrhythmicity is the variability in the repolarization of the
action potentials. This was investigated by Poincaré plots where
one APD90 value is plotted as a function of the preceding APD90
value (Fig. 6a, b). Application of 3.0 μM dofetilide resulted in a
larger dispersion in variability for some of the hearts while for the
combination group with 0.1 μM ICA and 1.0 μM dofetilide, no
major increase in variability was observed. This was quantified
by calculating short-term variability (STV) showing a part of the
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Poincaré plots generated by plotting one APD90 against the next to
illustrate beat-to-beat instability in repolarization. Instability of
dofetilide in a concentration of 3.0 μM is observed in two of the
experiments by increased complexity of the plot. No instability was
observed with the combination of ICA (0.1 μM) and dofetilide
(1.0 μM). In the Poincaré plot, each color represents one experiment
(seven in total in each group) at baseline and during drug treatment. b
To quantify the observations in the Poincaré plots, short-term variability
in repolarization was calculated. These analyses confirm two of the
3.0 μM hearts having a large variability. c Representative traces
displaying triangulation of the action potential by dofetilide (3.0 μM).
Triangulation, which is a measure for the time in phase 3 repolarization,
was calculated by APD90-APD30. ***significant difference between the
control and dofetilide (3.0 μM). †††significant difference from ICA
(0.1 μM)
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hearts with increased beat-to-beat dispersion in repolarization.
However, although two of the six hearts had a profound increase
in STV, the mean STV was not statistically significant (Fig. 6c).
Finally, an increased triangulation, calculated as the time pe-
riod between APD30 and APD90, has been suggested to be a
measure of proarrhythmicity [13]. This time period has been
termed the vulnerable window,where there is a risk of experienc-
ing early after-depolarizations, which may develop into arrhyth-
mia [14]. Dofetilide has previously been reported to increase
triangulation [23], and, indeed, 3.0 μM dofetilide was calculated
to increase triangulation in these guinea pig hearts compared to
the control and ICA (0.1 μM). Both 1.0 μMdofetilide alone and
together with 0.1 μM ICA revealed a trend toward increased
triangulation compared to the control.
Discussion
Combination therapy has the potential to reduce the dose of
class III antiarrhythmics needed while maintaining their anti-
AF efficacy. Amiodarone is among the most commonly pre-
scribed antiarrhythmics, but its use is limited by severe dose-
related non-cardiac side effects. Dofetilide improves atrial fi-
brillation and atrial flutter conversion rates, but with increas-
ing doses grows the risk of TdP.
The SK channel is a novel, not yet clinically tested,
target for treatment of AF. Pharmacological inhibition of
these channels increases aERP in both human and exper-
imental models and protects against AF in animal models
[8, 30, 31]. SK channels are highly interesting in an AF
perspective, not only because SK channels in the heart
primarily seem to be of functional importance in the atria
but also due to the fact that SK channels are gated by
submicromolar intracellular calcium concentrations. This
gives SK channels a potential pivotal role in sustaining
AF, in particular in newly developed AF, where intracel-
lular calcium handling is compromised [37]. An increased
ISK during AF would be expected to have a profound
effect on the repolarization leading to shorter action po-
tentials and decreased refractoriness [34], which would be
expected to be a substrate for the maintenance of AF [21].
However, whether this is the mechanism making SK
channel blockers antiarrhythmic in several different
models of AF still remains to be investigated.
Prolongation of atrial effective refractory period is be-
lieved to be an important electrophysiological principle
for treating AF [5]. At a subefficacious concentration in
monotherapy, dofetilide increased aERP to a similar ex-
tent as the combination of ICA and dofetilide. However,
only the combination of ICA and dofetilide significantly
reduced the AF duration. This discrepancy shows that
aERP measurements during sinus rhythm are not the only
pivotal parameter in evaluating the antiarrhythmic poten-
tial of a given compound. A potential explanation for the
additive effect by ICA is that, during AF, the intracellular
diastolic Ca2+ concentration rises [22], which may lead to
an increased activation of SK channels [34]. An increased
ISK during AF would have an effect on repolarization in
both the diastolic interval and during the action potential.
As the diastolic interval is profoundly depolarized to po-
tentials around −65 mV during AF, the majority of the
cardiac sodium channels will be inactivated [28, 32],
which will lead to reduced upstroke velocity of the action
potential and reduced conduction velocity. With an
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increased ISK during AF, a fraction of the K
+ conductance
in the diastolic interval will be originating from the SK
channels. As a consequence, pharmacological blockage of
these SK channels could, during AF, reduce the repolari-
zation force throughout the depolarization, which could
provide longer action potentials, and thereby prolong the
time before reaching the point where an adequate fraction
of sodium channels are released from voltage- and time-
dependent inactivation to support a new action potential
upstroke. Hence, an increased ISK during AF action po-
tentials would be expected to reduce both APD and ERP,
whereby pharmacological inhibition of SK channels could
potentially prolong refractoriness. This is expected to be
antiarrhythmic. Based on this, we suggest that pharmaco-
logical blockage of SK channels has a more profound
effect during AF, which would explain the relatively small
electrophysiological changes recorded following SK
channel block of atrial tissue in sinus rhythm.
Dofetilide has predominantly been reported to affect
the refractoriness of the atria through the hERG1 block.
The hERG1 channels underlie the rapid delayed rectifier
K+ current IKr, which plays an important role in phase 3
repolarization. As the combination of ICA and dofetilide
drastically reduces the AF duration as compared to the
respective monotherapies, our results indicate a synergis-
tic effect by combining these two compounds having dif-
ferent molecular targets.
The prolongation of QT and subsequent risk of TdP
caused by dofetilide has been well established in the clin-
ic [25]. At a concentration that was effective in the pre-
vention of AF as a monotherapy, dofetilide produced a
marked increase in the QT interval in isolated guinea pig
hearts. When subefficacious monotherapy concentrations
of ICA and dofetilide were combined, it not only showed
an anti-AF effect, but in addition, the combination did not
increase the QT interval significantly. Another important
parameter in investigating potential proarrhythmic ven-
tricular side effects is dispersion in repolarization. When
hearts where treated with an effective dose of dofetilide,
some of the hearts showed a clear increase in the beat-to-
beat repolarization time. In addition, the spatial dispersion
in repolarization between the right and left ventricle was
found increased with 3.0 μM dofetilide. Neither increase
in temporal nor in spatial dispersion was observed in the
combination group of ICA and dofetilide. Furthermore,
triangulation of the ventricular action potential has also
been reported as a critical parameter for estimating
proarrhythmicity [14]. At 3.0 μM, dofetilide significantly
increased triangulation. Reducing the dose to 1.0 μM,
both with and without ICA decreased the degree of trian-
gulation, confirming that the dose of dofetilide is impor-
tant in making the action potential more triangular. The
results thereby show that the combination of an SK
channel blocker and dofetilide applied in lower concen-
trations may maintain antiarrhythmic efficacy and, at the
same time, reduce the risk of TdP and other ventricular
arrhythmias.
Amiodarone is one of the most commonly used anti-
AF drugs. Chronic treatment of amiodarone is often re-
stricted by non-cardiac dose-dependent adverse effects
[41]. It is therefore of great interest to investigate whether
the effective concentration of amiodarone can be lowered
by combining it with another antiarrhythmic compound.
Amiodarone (1.0 μM) and 0.1 μM ICA applied as mono-
therapies both gave borderline prolongation of ERP.
When combining the compounds, a drastic ERP prolon-
gation was found. This additive effect was confirmed
when analyzing AF duration where the monotherapies
were ineffective in shortening AF duration, and the com-
bination of ICA and amiodarone gave profound shorten-
ing. To investigate potential ventricular adverse effects of
the compounds, the QT intervals were analyzed.
Amiodarone did not increase the QT interval at either a
high concentration or lower concentration in combination
with ICA. Our results thereby reveal that by combining an
SK blocker with the multichannel blocker amiodarone, a
lower dose of amiodarone is needed to reduce AF
duration.
Study limitations
In the ACh and burst pacing Langendorff model, AF is in-
duced acutely and the impact of structural remodeling, known
to be present in more persistent forms of AF, is therefore not
accounted for. Hence, the investigations performed do not
fully reflect the conditions observed in the clinic and extrapo-
lation of data should, therefore, be performed with caution.
For example, in long-lasting human AF, the expression of
SK channels has been reported to be reduced [31].
Treatment of patients with longer periods of AF with SK
channel blockers may therefore be challenging.
Conclusion
The combination of ICA with dofetilide or amiodarone in
concentrations ineffective as independent monotherapies re-
duced the AF durations compared to both control and mono-
therapies. At a concentration that was effective as a monother-
apy, dofetilide produced a prolongation of the QT interval that
was not observed with effective doses of ICA and dofetilide in
combination.
Hence, the combination of subefficacious concentrations of
an SK channel blocker and either dofetilide or amiodarone
could possibly maintain the anti-AF properties, whereby the
risk of ventricular arrhythmias and non-cardiac side effects
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will be reduced. Although these observations suggest poten-
tial new treatment modalities for AF, a thorough understand-
ing of the pathophysiology, optimal pharmacokinetics, and
potential drug–drug interactions is a prerequisite to determine
whether the observed findings can translate into the human
in vivo situation.
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